ATE440096T1 - Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung - Google Patents
Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendungInfo
- Publication number
- ATE440096T1 ATE440096T1 AT01999258T AT01999258T ATE440096T1 AT E440096 T1 ATE440096 T1 AT E440096T1 AT 01999258 T AT01999258 T AT 01999258T AT 01999258 T AT01999258 T AT 01999258T AT E440096 T1 ATE440096 T1 AT E440096T1
- Authority
- AT
- Austria
- Prior art keywords
- substituents
- group optionally
- production
- hydrocarbon group
- pyridyl groups
- Prior art date
Links
- -1 3-PYRIDYL GROUPS Chemical group 0.000 title 1
- 150000007979 thiazole derivatives Chemical class 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000003431 steroids Chemical class 0.000 abstract 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 229940122014 Lyase inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010036976 Prostatism Diseases 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000002697 lyase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000373868 | 2000-12-08 | ||
| PCT/JP2001/010723 WO2002046186A1 (en) | 2000-12-08 | 2001-12-07 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE440096T1 true ATE440096T1 (de) | 2009-09-15 |
Family
ID=18843165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01999258T ATE440096T1 (de) | 2000-12-08 | 2001-12-07 | Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7067537B2 (de) |
| EP (1) | EP1348706B1 (de) |
| JP (1) | JP2008266349A (de) |
| AT (1) | ATE440096T1 (de) |
| AU (1) | AU2002221080A1 (de) |
| CA (1) | CA2431171A1 (de) |
| DE (1) | DE60139639D1 (de) |
| WO (1) | WO2002046186A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1176195B1 (de) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Verfahren zur kontrolle der aktivität von immunologisch funktionellem molekül |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| BR0313755A (pt) * | 2002-08-23 | 2005-06-21 | Rigel Pharmaceuticals Inc | Composto, métodos para inibir a replicação ou proliferação de um vìrion da hepatite c e para tratar ou prevenir uma infecção por hcv, e, composição |
| US7071223B1 (en) * | 2002-12-31 | 2006-07-04 | Pfizer, Inc. | Benzamide inhibitors of the P2X7 receptor |
| EP1620412A2 (de) | 2003-05-02 | 2006-02-01 | Rigel Pharmaceuticals, Inc. | Heterocyclische verbindungen und deren hydroisomere |
| MXPA05012086A (es) * | 2003-05-12 | 2006-02-22 | Pfizer Prod Inc | Inhibidores de benzamida del receptor p2x7. |
| US7410979B2 (en) | 2003-11-19 | 2008-08-12 | Rigel Pharmaceuticals, Inc. | Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections |
| ATE396718T1 (de) * | 2003-12-19 | 2008-06-15 | Rigel Pharmaceuticals Inc | Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion |
| US7514434B2 (en) | 2004-02-23 | 2009-04-07 | Rigel Pharmaceuticals, Inc. | Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof |
| JP2008504360A (ja) * | 2004-06-29 | 2008-02-14 | ファイザー・プロダクツ・インク | ヒドロキシル保護された前駆体を脱保護することによる５−［４−（２−ヒドロキシ−プロピル）−３，５−ジオキソ−４，５−ジヒドロ−３ｈ−１，２，４−トリアジン−２−イル］−ベンズアミド誘導体の製造方法 |
| JP2008504363A (ja) * | 2004-06-29 | 2008-02-14 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Ｐ２ｘ７受容体のベンズアミド阻害剤を利用する併用療法 |
| CA2606106A1 (en) | 2005-05-02 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses |
| US9085566B2 (en) | 2007-02-02 | 2015-07-21 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and related disorders |
| AU2008214095B2 (en) * | 2007-02-02 | 2014-07-10 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| US9233941B2 (en) | 2007-02-02 | 2016-01-12 | Baylor College Of Medicine | Methods and compositions for the treatment of body weight related disorders |
| US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
| US9212179B2 (en) | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| CA2966280A1 (en) | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Diarylhydantoin compounds |
| JP2011513203A (ja) * | 2008-03-14 | 2011-04-28 | 大塚製薬株式会社 | Ｍｍｐ−２及び／又はｍｍｐ−９阻害剤 |
| GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| LT2718270T (lt) * | 2011-06-10 | 2022-08-10 | Merck Patent Gmbh | Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai |
| US20130184280A1 (en) * | 2011-12-21 | 2013-07-18 | Telik, Inc. | Substituted thiazoles as vegfr2 kinase inhibitors |
| CA2885155C (en) | 2012-11-16 | 2021-02-16 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters |
| EP3652159B1 (de) * | 2017-07-11 | 2023-01-18 | Cyteir Therapeutics, Inc. | Substituierte thiazol derivative als rad51 hemmstoffe zur behandlung von krebserkrankungen, autoimmun- und neurodegenerativen zuständen |
| CN115515940A (zh) * | 2020-02-28 | 2022-12-23 | 德州大学系统董事会 | 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂 |
| CN117185961A (zh) * | 2023-09-08 | 2023-12-08 | 天津师范大学 | 一种基于4-氰基苯甲酰胺有机弹性室温磷光晶体及其制备方法与应用 |
| WO2025165774A1 (en) * | 2024-02-01 | 2025-08-07 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| WO2025165773A1 (en) * | 2024-02-01 | 2025-08-07 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3821384A (en) | 1972-10-06 | 1974-06-28 | Uniroyal Inc | Pharmaceutical compositions containing a4-aryl-2-(3-pyridyl)thiazole and methods of using same |
| US4153703A (en) | 1977-06-30 | 1979-05-08 | Uniroyal, Inc. | Method of controlling insects and acarids with certain aryl-substituted thiazoles |
| EP0149884B1 (de) | 1983-09-09 | 1992-12-16 | Takeda Chemical Industries, Ltd. | 5-Pyridyl-1,3-Thiazol-Derivate, ihre Herstellung und Anwendung |
| NZ221729A (en) | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
| ZA882717B (en) | 1987-04-22 | 1988-10-17 | Merrell Dow Pharmaceuticals Inc. | 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors |
| US4966898A (en) | 1989-08-15 | 1990-10-30 | Merrell Dow Pharmaceuticals Inc. | 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors |
| WO1992015404A1 (en) | 1991-03-01 | 1992-09-17 | S.L. Electrostatic Technology, Inc. | Powder coating method for producing circuit board laminae and the like |
| US5457102A (en) | 1994-07-07 | 1995-10-10 | Janssen Pharmaceutica, N.V. | Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives |
| CZ287434B6 (en) | 1992-03-31 | 2000-11-15 | British Tech Group | Use of steroids, substituted in position 17, steroids functioning as carcinostatics and pharmaceutical preparation containing thereof |
| GB9310635D0 (en) | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
| EP0721943A4 (de) | 1993-09-30 | 1996-09-04 | Yamanouchi Pharma Co Ltd | Azol-derivate und pharmazeutische präparate |
| WO1996014090A1 (en) | 1994-11-07 | 1996-05-17 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
| PL322028A1 (en) * | 1995-03-01 | 1998-01-05 | Yamanouchi Pharma Co Ltd | Derivatives of imidazoles and pharmaceutic composition containing them |
| WO1997000257A1 (en) | 1995-06-14 | 1997-01-03 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
| NZ327041A (en) | 1996-02-14 | 1999-11-29 | Hoechst Marion Roussel Inc | 17-beta-cyclopropyl(amino/oxy) 4-aza steriods as active inhibitors of testosterone 5-alpha-reductase and C17-20-lyase |
| CA2250908C (en) | 1996-04-30 | 2012-03-13 | Takeda Chemical Industries, Ltd. | Combined use of gnrh agonist and antagonist |
| AU4015497A (en) * | 1996-08-26 | 1998-03-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thiazole derivatives useful as selective inhibitors of pde-iv |
| WO1998008844A1 (de) | 1996-08-26 | 1998-03-05 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thiazol-derivate als selektive inhibitoren der pde-iv |
| JPH10195056A (ja) | 1996-11-12 | 1998-07-28 | Takeda Chem Ind Ltd | 縮合ベンゼン誘導体、その製造法および剤 |
| EP0968209A1 (de) * | 1997-01-28 | 2000-01-05 | Merck & Co., Inc. | Thiazole benzenesulfonamide als beta3-agonisten zur behandlung von diabetes und fettleibigkeit |
| WO1998037070A1 (en) * | 1997-02-21 | 1998-08-27 | Takeda Chemical Industries, Ltd. | Fused ring compounds, process for producing the same and use thereof |
| JPH1179993A (ja) | 1997-09-05 | 1999-03-23 | Sumitomo Pharmaceut Co Ltd | 免疫抑制剤 |
| EP1028110B1 (de) | 1997-10-02 | 2004-04-14 | Daiichi Pharmaceutical Co., Ltd. | Dihydronaphthalinderivate und verfahren zur herstellung derselben |
| ATE257703T1 (de) | 1997-10-27 | 2004-01-15 | Takeda Chemical Industries Ltd | 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes |
| CA2328973A1 (en) | 1998-04-23 | 1999-10-28 | Akio Ojida | Naphthalene derivatives, their production and use |
| EP1161415B1 (de) | 1999-03-15 | 2005-07-13 | Axys Pharmaceuticals, Inc. | N-cyanomethylamide als protease inhibitoren |
| IL146105A (en) | 1999-04-23 | 2005-09-25 | Tadeda Pharmaceutical Company | 5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor |
| JP2000302680A (ja) | 1999-04-23 | 2000-10-31 | Takeda Chem Ind Ltd | 脳保護剤 |
| CA2381215A1 (en) | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | P38map kinase inhibitors |
| AU7950100A (en) * | 1999-10-22 | 2001-05-08 | Takeda Chemical Industries Ltd. | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof |
| AU2001245764A1 (en) | 2000-03-15 | 2001-09-24 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as protease inhibitors |
| WO2001083461A1 (en) * | 2000-04-28 | 2001-11-08 | Shionogi & Co., Ltd. | Thiazole and oxazole derivatives |
| WO2003027101A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors |
-
2001
- 2001-12-07 AU AU2002221080A patent/AU2002221080A1/en not_active Abandoned
- 2001-12-07 AT AT01999258T patent/ATE440096T1/de not_active IP Right Cessation
- 2001-12-07 EP EP01999258A patent/EP1348706B1/de not_active Expired - Lifetime
- 2001-12-07 DE DE60139639T patent/DE60139639D1/de not_active Expired - Lifetime
- 2001-12-07 US US10/433,910 patent/US7067537B2/en not_active Expired - Fee Related
- 2001-12-07 WO PCT/JP2001/010723 patent/WO2002046186A1/ja not_active Ceased
- 2001-12-07 CA CA002431171A patent/CA2431171A1/en not_active Abandoned
-
2008
- 2008-06-12 JP JP2008154723A patent/JP2008266349A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2431171A1 (en) | 2002-06-13 |
| US7067537B2 (en) | 2006-06-27 |
| DE60139639D1 (de) | 2009-10-01 |
| WO2002046186A1 (en) | 2002-06-13 |
| EP1348706B1 (de) | 2009-08-19 |
| EP1348706A1 (de) | 2003-10-01 |
| JP2008266349A (ja) | 2008-11-06 |
| EP1348706A4 (de) | 2005-08-10 |
| US20040072876A1 (en) | 2004-04-15 |
| AU2002221080A1 (en) | 2002-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE440096T1 (de) | Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung | |
| ATE253545T1 (de) | Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren | |
| DE60309829D1 (de) | Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon | |
| NZ532494A (en) | Dibenzylamine compound and medicinal use thereof | |
| BRPI0615111B8 (pt) | composto, composição farmacêutica, e, uso do composto | |
| ATE334973T1 (de) | Chinazolinverbindungen | |
| ECSP055611A (es) | Compuestos miméticos de glucocorticoides, métodos de prepararlos, composiciones farmacéuticas | |
| DE60322713D1 (de) | Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung | |
| EE200200148A (et) | Kinasoliini derivaadid, nende valmistamise meetodning kasutamine | |
| IS7170A (is) | Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra | |
| FI924397A0 (fi) | Substituerade pyrimidiner. | |
| DE69923300D1 (de) | Cycloalken-derivate, verfahren zu ihrer herstellung und ihre verwendung | |
| DE69428142D1 (de) | Quinolin- oder Quinazolinderivate, deren Herstellung und Verwendung | |
| ATE144772T1 (de) | Piperazinderivate | |
| ATE159514T1 (de) | Substituierte aminsäure derivate verwendbar für die behandlung von arteriosclerosis | |
| NO20025035D0 (no) | Oksadiazolderivater som har anticancer-effekter | |
| ATE513821T1 (de) | Thiadiazolin-derivate zur behandlung von krebs | |
| DE60027034D1 (de) | 1-substituierte-phenyl-1-(1h-imidazol-4-yl)alkohole, verfahren zu deren herstellung sowie deren verwendung | |
| DE3867899D1 (de) | Verfahren zur herstellung von 4-amino-androstendion-derivaten. | |
| ATE502030T1 (de) | Imidazolderivate, verfahren zu deren herstellung und deren verwendung | |
| ATE187448T1 (de) | Morpholinderivate | |
| ATE214064T1 (de) | Indane-1-ol derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
| NO20013921D0 (no) | Heterosykliske derivater som inhibitorer av faktor XA | |
| DE69725167D1 (de) | N-benzolsulfonyl-l-prolin derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
| ITMI920082A1 (it) | Derivati solforati di acidi biliari |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |